CRB Webinars Session 4: Thursday, August 12, 2021 • 5:00 P.M. EDT
Crispr Based Genome Editing – Any Prospect For PGT?
By Helen O’Neill, Ph.D.
Thursday, August 12, 2021, 5:00 P.M. EDT • 1.0 Contact Hour PEER-approved
- Overview of Genome Editing Technologies
- Current State of the Landscape
- Controversies Encountered with Germline Genome Editing
- Comparing the Use of PGT and Reflecting on the Possibility of Germline Genome Editing as an Alternative Therapy
About our speaker:
Helen O’Neill, Ph.D.
University College London
London, United Kingdom
Dr. O’Neill is a lecturer in Reproductive and Molecular Genetics and Director for the MSc in Reproductive Science and Women’s Health at the Institute for Women’s Health, University College London (UCL). Her research focuses on preimplantation embryo development and the use of genome editing to assess understanding and treatment of disorders of infertility. Dr O’Neill has an honors degree in genetics, an MSc in prenatal genetics and fetal medicine from UCL, and she did her PhD and postdoctoral research on the genetics of ovarian development in the Department of Stem Cell Biology and Developmental Genetics at the National Institute for Medical Research. She lectures both masters and medical students and is active in public engagement involving genome editing. Dr. O’Neill is CEO and founder of Hertility Health, a precision medicine-based approach to reproductive health and fertility.